An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin

Alessandra Gianoncelli, Sara A. Bonini, Michela Bertuzzi, Michela Guarienti, Sara Vezzoli, Rajesh Kumar, Andrea Delbarba, Andrea Mastinu, Sandra Sigala, Pierfranco Spano, Luca Pani, Sergio Pecorelli, Maurizio Memo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Authorization to market a biosimilar product by the appropriate institutions is expected based on biosimilarity with its originator product. The analogy between the originator and its biosimilar(s) is assessed through safety, purity, and potency analyses. Objective: In this study, we proposed a useful quality control system for rapid and economic primary screening of potential biosimilar drugs. For this purpose, chemical and functional characterization of the originator rhEPO alfa and two of its biosimilars was discussed. Methods: Qualitative and quantitative analyses of the originator rhEPO alfa and its biosimilars were performed using reversed-phase high-performance liquid chromatography (RP-HPLC). The identification of proteins and the separation of isoforms were studied using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and two-dimensional gel electrophoresis (2D-PAGE), respectively. Furthermore, the biological activity of these drugs was measured both in vitro, evaluating the TF-1 cell proliferation rate, and in vivo, using the innovative experimental animal model of the zebrafish embryos. Results: Chemical analyses showed that the quantitative concentrations of rhEPO alfa were in agreement with the labeled claims by the corresponding manufacturers. The qualitative analyses performed demonstrated that the three drugs were pure and that they had the same amino acid sequence. Chemical differences were found only at the level of isoforms containing N-glycosylation; however, functional in vitro and in vivo studies did not show any significant differences from a biosimilar point of view. Conclusion: These rapid and economic structural and functional analyses were effective in the evaluation of the biosimilarity between the originator rhEPO alfa and the biosimilars analyzed.

Original languageEnglish
Pages (from-to)285-300
Number of pages16
JournalBioDrugs
Volume29
Issue number4
DOIs
Publication statusPublished - Sep 3 2015

Fingerprint

Biosimilar Pharmaceuticals
Erythropoietin
Electrophoresis, Gel, Two-Dimensional
Protein Isoforms
Economics
Pharmaceutical Preparations
Zebrafish
Reverse-Phase Chromatography
Glycosylation
Quality Control
Amino Acid Sequence
Mass Spectrometry
Lasers
Embryonic Structures
Animal Models
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology

Cite this

Gianoncelli, A., Bonini, S. A., Bertuzzi, M., Guarienti, M., Vezzoli, S., Kumar, R., ... Memo, M. (2015). An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. BioDrugs, 29(4), 285-300. https://doi.org/10.1007/s40259-015-0136-3

An Integrated Approach for a Structural and Functional Evaluation of Biosimilars : Implications for Erythropoietin. / Gianoncelli, Alessandra; Bonini, Sara A.; Bertuzzi, Michela; Guarienti, Michela; Vezzoli, Sara; Kumar, Rajesh; Delbarba, Andrea; Mastinu, Andrea; Sigala, Sandra; Spano, Pierfranco; Pani, Luca; Pecorelli, Sergio; Memo, Maurizio.

In: BioDrugs, Vol. 29, No. 4, 03.09.2015, p. 285-300.

Research output: Contribution to journalArticle

Gianoncelli, A, Bonini, SA, Bertuzzi, M, Guarienti, M, Vezzoli, S, Kumar, R, Delbarba, A, Mastinu, A, Sigala, S, Spano, P, Pani, L, Pecorelli, S & Memo, M 2015, 'An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin', BioDrugs, vol. 29, no. 4, pp. 285-300. https://doi.org/10.1007/s40259-015-0136-3
Gianoncelli, Alessandra ; Bonini, Sara A. ; Bertuzzi, Michela ; Guarienti, Michela ; Vezzoli, Sara ; Kumar, Rajesh ; Delbarba, Andrea ; Mastinu, Andrea ; Sigala, Sandra ; Spano, Pierfranco ; Pani, Luca ; Pecorelli, Sergio ; Memo, Maurizio. / An Integrated Approach for a Structural and Functional Evaluation of Biosimilars : Implications for Erythropoietin. In: BioDrugs. 2015 ; Vol. 29, No. 4. pp. 285-300.
@article{64414dccf9aa418db77e84063eaa3fd5,
title = "An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin",
abstract = "Background: Authorization to market a biosimilar product by the appropriate institutions is expected based on biosimilarity with its originator product. The analogy between the originator and its biosimilar(s) is assessed through safety, purity, and potency analyses. Objective: In this study, we proposed a useful quality control system for rapid and economic primary screening of potential biosimilar drugs. For this purpose, chemical and functional characterization of the originator rhEPO alfa and two of its biosimilars was discussed. Methods: Qualitative and quantitative analyses of the originator rhEPO alfa and its biosimilars were performed using reversed-phase high-performance liquid chromatography (RP-HPLC). The identification of proteins and the separation of isoforms were studied using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and two-dimensional gel electrophoresis (2D-PAGE), respectively. Furthermore, the biological activity of these drugs was measured both in vitro, evaluating the TF-1 cell proliferation rate, and in vivo, using the innovative experimental animal model of the zebrafish embryos. Results: Chemical analyses showed that the quantitative concentrations of rhEPO alfa were in agreement with the labeled claims by the corresponding manufacturers. The qualitative analyses performed demonstrated that the three drugs were pure and that they had the same amino acid sequence. Chemical differences were found only at the level of isoforms containing N-glycosylation; however, functional in vitro and in vivo studies did not show any significant differences from a biosimilar point of view. Conclusion: These rapid and economic structural and functional analyses were effective in the evaluation of the biosimilarity between the originator rhEPO alfa and the biosimilars analyzed.",
author = "Alessandra Gianoncelli and Bonini, {Sara A.} and Michela Bertuzzi and Michela Guarienti and Sara Vezzoli and Rajesh Kumar and Andrea Delbarba and Andrea Mastinu and Sandra Sigala and Pierfranco Spano and Luca Pani and Sergio Pecorelli and Maurizio Memo",
year = "2015",
month = "9",
day = "3",
doi = "10.1007/s40259-015-0136-3",
language = "English",
volume = "29",
pages = "285--300",
journal = "Clinical Immunotherapeutics",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - An Integrated Approach for a Structural and Functional Evaluation of Biosimilars

T2 - Implications for Erythropoietin

AU - Gianoncelli, Alessandra

AU - Bonini, Sara A.

AU - Bertuzzi, Michela

AU - Guarienti, Michela

AU - Vezzoli, Sara

AU - Kumar, Rajesh

AU - Delbarba, Andrea

AU - Mastinu, Andrea

AU - Sigala, Sandra

AU - Spano, Pierfranco

AU - Pani, Luca

AU - Pecorelli, Sergio

AU - Memo, Maurizio

PY - 2015/9/3

Y1 - 2015/9/3

N2 - Background: Authorization to market a biosimilar product by the appropriate institutions is expected based on biosimilarity with its originator product. The analogy between the originator and its biosimilar(s) is assessed through safety, purity, and potency analyses. Objective: In this study, we proposed a useful quality control system for rapid and economic primary screening of potential biosimilar drugs. For this purpose, chemical and functional characterization of the originator rhEPO alfa and two of its biosimilars was discussed. Methods: Qualitative and quantitative analyses of the originator rhEPO alfa and its biosimilars were performed using reversed-phase high-performance liquid chromatography (RP-HPLC). The identification of proteins and the separation of isoforms were studied using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and two-dimensional gel electrophoresis (2D-PAGE), respectively. Furthermore, the biological activity of these drugs was measured both in vitro, evaluating the TF-1 cell proliferation rate, and in vivo, using the innovative experimental animal model of the zebrafish embryos. Results: Chemical analyses showed that the quantitative concentrations of rhEPO alfa were in agreement with the labeled claims by the corresponding manufacturers. The qualitative analyses performed demonstrated that the three drugs were pure and that they had the same amino acid sequence. Chemical differences were found only at the level of isoforms containing N-glycosylation; however, functional in vitro and in vivo studies did not show any significant differences from a biosimilar point of view. Conclusion: These rapid and economic structural and functional analyses were effective in the evaluation of the biosimilarity between the originator rhEPO alfa and the biosimilars analyzed.

AB - Background: Authorization to market a biosimilar product by the appropriate institutions is expected based on biosimilarity with its originator product. The analogy between the originator and its biosimilar(s) is assessed through safety, purity, and potency analyses. Objective: In this study, we proposed a useful quality control system for rapid and economic primary screening of potential biosimilar drugs. For this purpose, chemical and functional characterization of the originator rhEPO alfa and two of its biosimilars was discussed. Methods: Qualitative and quantitative analyses of the originator rhEPO alfa and its biosimilars were performed using reversed-phase high-performance liquid chromatography (RP-HPLC). The identification of proteins and the separation of isoforms were studied using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and two-dimensional gel electrophoresis (2D-PAGE), respectively. Furthermore, the biological activity of these drugs was measured both in vitro, evaluating the TF-1 cell proliferation rate, and in vivo, using the innovative experimental animal model of the zebrafish embryos. Results: Chemical analyses showed that the quantitative concentrations of rhEPO alfa were in agreement with the labeled claims by the corresponding manufacturers. The qualitative analyses performed demonstrated that the three drugs were pure and that they had the same amino acid sequence. Chemical differences were found only at the level of isoforms containing N-glycosylation; however, functional in vitro and in vivo studies did not show any significant differences from a biosimilar point of view. Conclusion: These rapid and economic structural and functional analyses were effective in the evaluation of the biosimilarity between the originator rhEPO alfa and the biosimilars analyzed.

UR - http://www.scopus.com/inward/record.url?scp=84941425068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941425068&partnerID=8YFLogxK

U2 - 10.1007/s40259-015-0136-3

DO - 10.1007/s40259-015-0136-3

M3 - Article

AN - SCOPUS:84941425068

VL - 29

SP - 285

EP - 300

JO - Clinical Immunotherapeutics

JF - Clinical Immunotherapeutics

SN - 1173-8804

IS - 4

ER -